hemotune initiates joint feasibility project on the HemoSystem with AstraZeneca

hemotune AG, the Schlieren-based MedTech company known for its magnetic blood purification platform announces a joint feasibility project with the global pharmaceutical company AstraZeneca.

The project is based on the HemoSystem, a therapeutic blood purification platform under development by hemotune which is designed for the selective and efficient removal of large biomolecules directly from blood. Magnetic beads are introduced to an extracorporeal circuit similar to a dialysis machine. While flowing with the blood, they bind to target compounds through specific binders on their surface. Before the blood is returned to the patient, beads and bound targets are highly efficiently removed in a magnetic filter.

Lukas Langenegger, hemotune's CEO and Co-Founder states: "In the last years we have put a lot of effort in developing our technology consisting of the device, disposable and magnetic beads platform. We are very happy to work with one of the leading global pharma companies to explore applications of the HemoSystem."

hemotune is a MedTech start-up based in Schlieren, Switzerland, developing a revolutionary blood purification platform. This combines cutting-edge scientific results from biomedicine and nanotechnology to develop the HemoSystem, a new treatment platform that combines the benefits of medical devices and biotechnology. The company, which was founded in 2017 as a spin-off of ETH Zurich was accelerated by Wyss Zurich and supported by Venture Kick, Gebert Rüf Foundation, Innosuisse, H2020, and EIT Health.

In addition, the company has won several prestigious awards such as the Swiss Technology Award 2020, was recognized by Forbes magazine as the No.1 Spin-off to watch in 2021, won a German Innovation Award in 2022, was a finalist for the Swiss Economic Award 2022, won a Red Dot Design Concept Award 2022 and was recognized by Frost & Sullivan with the European Technology Leadership Award in Blood Purification Technology 2022 for the HemoSystem. hemotune also was selected for the TOP 100 Swiss Startup Award from 2020 to 2022 and participated in the Venture Leaders Medtech in 2021.